Medical Imaging Surgical Apparatus Endoscopy Equipment

PUBLISHER: 360iResearch | PRODUCT CODE: 2098324

PUBLISHER: 360iResearch | PRODUCT CODE: 2098324

Endoscopic Vessel Harvesting Market - Global Forecast 2026-2032

PUBLISHED: July 27, 2026

PAGES: 186 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

List of Tables

The Endoscopic Vessel Harvesting Market is projected to grow by USD 838.17 million at a CAGR of 5.33% by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 582.40 million
Estimated Year [2026]	USD 612.28 million
Forecast Year [2032]	USD 838.17 million
CAGR (%)	5.33%

Endoscopic vessel harvesting (EVH) has become an important minimally invasive technique in coronary artery bypass grafting and selected peripheral vascular procedures, enabling clinicians to retrieve the saphenous vein or radial artery through small incisions rather than long open surgical exposures. The clinical rationale is well established: reduced incision length can lower wound-related morbidity, improve patient comfort, support earlier mobilization, and enhance cosmetic outcomes when performed by trained teams using appropriate protocols. As cardiovascular disease remains a leading global cause of mortality, demand for durable revascularization and lower-trauma surgical approaches continues to shape adoption of EVH systems, disposable instruments, visualization platforms, insufflation components, and training programs. The endoscopic vessel harvesting landscape is influenced by cardiac surgery volumes, rising diabetes and obesity prevalence, infection-prevention priorities, hospital quality metrics, and the need to standardize conduit quality. Current decision-making increasingly centers on balancing minimally invasive access with graft integrity, operator learning curves, procedural efficiency, and total cost of care. For healthcare executives, suppliers, and surgical leaders, EVH is not simply a device category; it is a perioperative capability that links cardiovascular outcomes, surgical workforce development, operating room productivity, and value-based care objectives.

Transformative Shifts in the Endoscopic Vessel Harvesting Landscape

The endoscopic vessel harvesting landscape is undergoing a structural shift from procedure adoption toward performance optimization. Hospitals are moving beyond whether EVH should be used and are focusing on how consistently it can deliver high-quality conduits with fewer wound complications, predictable operating times, and reproducible results across surgical teams. This shift is supported by better visualization technologies, improved ergonomic instruments, standardized tunnel creation techniques, and enhanced training pathways for physician assistants, surgical technologists, nurses, and cardiac surgery teams. Another major transformation is the expanding emphasis on patient-centered recovery. In populations with higher wound-risk profiles, including patients with diabetes, obesity, peripheral vascular disease, and advanced age, minimally invasive harvesting can be strategically aligned with infection reduction, shorter rehabilitation timelines, and improved satisfaction. At the same time, procurement teams are increasingly evaluating EVH platforms through evidence-based criteria such as conduit handling, thermal spread control, ease of branch ligation, device reliability, and compatibility with existing operating room workflows. Regulatory scrutiny, clinical documentation, and post-market surveillance expectations are also encouraging manufacturers and providers to prioritize safety, traceability, and training. The result is a more mature environment in which EVH adoption depends on clinical governance, surgeon confidence, staff competency, and measurable improvements in perioperative quality rather than device availability alone.

Cumulative Impact of Artificial Intelligence on Endoscopic Vessel Harvesting

Artificial intelligence is beginning to influence endoscopic vessel harvesting through adjacent and enabling capabilities rather than replacing the clinician's technical role. AI-enabled surgical video analytics can support training by reviewing endoscopic footage, identifying procedural steps, and helping teams recognize patterns associated with efficient dissection, branch management, or potential conduit trauma. In perioperative planning, machine learning models can help stratify wound complication risk by incorporating variables such as diabetes status, body mass index, renal function, smoking history, vascular disease, and prior surgical history, allowing hospitals to determine which patients may benefit most from minimally invasive harvest approaches. AI may also support operating room scheduling, inventory optimization, and device utilization tracking by analyzing procedure duration, disposable consumption, and staff availability. In quality improvement programs, natural language processing and structured data analytics can help extract outcomes from electronic health records, including wound infection, readmission, reintervention, and graft-related indicators. The cumulative impact of AI is therefore expected to be strongest where it enhances decision support, training consistency, documentation quality, and operational efficiency. However, AI use in EVH must remain clinically validated, transparent, privacy-compliant, and integrated with surgeon-led governance. The most credible applications will be those that improve measurable care processes without introducing workflow burden or unverified claims about clinical superiority.

Key Regional Insights for Endoscopic Vessel Harvesting

Asia-Pacific is characterized by a rising cardiovascular disease burden, expanding tertiary cardiac care capacity, and growing interest in minimally invasive surgical recovery pathways. Countries with large patient populations and ongoing hospital infrastructure investment are strengthening the relevance of EVH, although adoption varies by reimbursement, training access, and availability of specialized cardiac surgery teams. Europe reflects a highly regulated and clinically evidence-driven environment, with adoption supported by cardiac surgery expertise, hospital quality standards, and emphasis on patient safety, while procurement policies and national reimbursement structures shape technology diffusion. North America demonstrates comparatively mature utilization, supported by established coronary artery bypass grafting programs, quality reporting practices, infection-control initiatives, and broader access to advanced surgical technologies. In this region, EVH decisions are often tied to evidence-based care pathways, operating room efficiency, and outcomes monitoring. Latin America shows selective but increasing interest in EVH, particularly in urban cardiac centers and private healthcare networks where minimally invasive techniques are used to improve patient experience and reduce wound-related complications; however, affordability and uneven access to specialized training can influence broader penetration. Africa presents a heterogeneous landscape, where access to cardiac surgery remains concentrated in select urban centers; EVH opportunities are closely linked to broader investments in cardiovascular infrastructure, surgical training, device availability, and affordability. The Middle East is seeing EVH relevance grow in advanced cardiac centers, especially in countries investing in specialty hospitals, medical tourism, and cardiovascular centers of excellence.

Key Group Insights for Endoscopic Vessel Harvesting

NATO countries overlap significantly with advanced healthcare systems in North America and Europe, where surgical readiness, standardized procurement, regulatory compliance, and interoperable clinical training frameworks can support consistent adoption of minimally invasive harvesting practices in high-acuity cardiovascular care. The G7 economies generally have stronger access to advanced surgical technology, structured clinical governance, and established cardiac surgery ecosystems, making EVH evaluation more closely tied to quality metrics, staff productivity, and total procedural value. BRICS countries present diverse conditions: large patient populations and growing cardiovascular demand support long-term relevance, while differences in hospital funding, local manufacturing capability, specialist availability, and public-private care models influence implementation. The European Union provides a rigorous regulatory and clinical environment in which EVH adoption depends on documented safety, procurement value, training compliance, and alignment with national healthcare quality priorities. Within ASEAN, the endoscopic vessel harvesting opportunity is linked to expanding cardiac care capacity, rising noncommunicable disease prevalence, and increasing investment in minimally invasive surgical capabilities across major metropolitan hospitals. Adoption is likely to remain concentrated where specialist training, device access, and reimbursement support are strongest. In the GCC, advanced hospital infrastructure, high cardiovascular risk related to diabetes and obesity, and strategic investment in specialized care support interest in EVH as part of premium cardiac surgery programs and infection-prevention initiatives.

Key Country Insights for Endoscopic Vessel Harvesting

China's large cardiovascular patient base, rapid hospital modernization, and expanding specialist capacity make EVH increasingly relevant, although training scale and procurement consistency remain important. The United States remains a highly influential EVH environment due to its large cardiac surgery infrastructure, emphasis on hospital quality metrics, and adoption of technologies that support faster recovery and lower wound morbidity. Japan's aging population, high standards for surgical quality, and advanced hospital systems support careful use of minimally invasive harvesting. India faces high coronary artery disease prevalence and a large surgical need, with EVH adoption strongest in private and advanced tertiary hospitals where affordability and clinical differentiation matter. Germany's strong surgical infrastructure and medical technology adoption support evidence-led EVH use, while the United Kingdom emphasizes clinical governance, cost-effectiveness, and standardized care pathways. Australia benefits from structured cardiac care networks and quality-driven surgical practice. France evaluates EVH within a framework of patient safety, reimbursement discipline, and specialized cardiovascular care, and South Korea's advanced hospital infrastructure and technology-forward clinical environment support EVH integration in high-performing cardiovascular centers. Italy and Spain have established cardiac surgery programs where minimally invasive recovery, wound management, and hospital efficiency are important considerations. Canada's use is shaped by publicly funded healthcare priorities, regional cardiac centers, and evidence-based procurement decisions. Russia's adoption is concentrated in advanced cardiac centers and shaped by regional disparities in healthcare infrastructure. Brazil has a substantial cardiovascular disease burden and established cardiac surgery expertise in major centers, making EVH relevant where cost, reimbursement, and access to trained teams align. Mexico shows growing interest in minimally invasive cardiac surgery within leading urban hospitals, with adoption influenced by private-sector capacity and specialist training availability.

Actionable Recommendations for Endoscopic Vessel Harvesting Leaders

Industry leaders should prioritize evidence-based differentiation by demonstrating how EVH platforms support conduit quality, reduce harvest-site complications, and improve workflow consistency under real clinical conditions. Device developers should invest in ergonomic design, visualization quality, thermal safety, reliable branch sealing, and intuitive instrument control to reduce operator variability. Training must be treated as a core value driver, not an optional add-on; structured simulation, proctored onboarding, competency assessment, and continuing education can improve adoption confidence and reduce learning-curve risk. Hospitals should build multidisciplinary EVH governance involving cardiac surgeons, physician assistants, nurses, infection-control teams, procurement leaders, and quality officers to align device selection with patient outcomes and operational needs. Suppliers should support data capture and post-procedure review, enabling institutions to monitor wound events, conversion rates, harvest time, conduit integrity, and readmissions. Market access teams should tailor strategies by region, recognizing that advanced economies may prioritize quality metrics and total cost of care, while emerging systems may require flexible procurement, local training partnerships, and affordability models. Leaders should also monitor AI-enabled training analytics and digital documentation tools, but only deploy solutions supported by validation, cybersecurity safeguards, and clear clinical utility. Above all, competitive advantage will come from combining safe technology, repeatable training, credible evidence, and integration into value-based cardiovascular care pathways.

Research Methodology for Endoscopic Vessel Harvesting Analysis

A robust research methodology for endoscopic vessel harvesting should combine secondary evidence review, clinical literature assessment, regulatory analysis, and structured primary insights from cardiovascular stakeholders. Secondary research should include peer-reviewed cardiac surgery studies, clinical practice guidelines, public health data on cardiovascular disease, regulatory databases, hospital quality publications, and procedure-related safety literature. Primary research should engage cardiac surgeons, physician assistants, operating room nurses, procurement specialists, hospital administrators, infection-control experts, and medical device distributors to understand real-world adoption drivers, procedural barriers, training needs, and purchasing criteria. Data validation should rely on triangulation across clinical evidence, healthcare infrastructure indicators, reimbursement frameworks, and expert interviews. Special attention should be given to differences between saphenous vein and radial artery harvesting, open versus endoscopic techniques, patient risk profiles, and regional care delivery models. The methodology should exclude unsupported assumptions about commercial scale and should avoid estimates or forecasts when the objective is executive-level strategic interpretation. Quality control requires source verification, consistency checks, recency assessment, and clinical plausibility review. This approach ensures that conclusions about EVH adoption, innovation, and regional dynamics remain grounded in verifiable evidence and practical healthcare realities.

Conclusion: Strategic Outlook for Endoscopic Vessel Harvesting

Endoscopic vessel harvesting continues to play a meaningful role in modern cardiovascular surgery by aligning minimally invasive technique with patient recovery, wound-risk reduction, and operating room efficiency. Its strategic importance is strongest where hospitals can combine skilled operators, standardized protocols, reliable devices, and rigorous outcomes monitoring. The landscape is being reshaped by value-based care, growing cardiovascular disease burden, demand for lower-trauma procedures, and digital tools that support training and quality improvement. Regional adoption remains uneven, reflecting differences in cardiac surgery capacity, reimbursement, procurement models, and workforce development. Artificial intelligence and advanced analytics may further strengthen EVH programs by improving risk stratification, training feedback, and workflow visibility, provided that implementation is clinically validated and ethically governed. For industry leaders, the path forward depends on moving beyond product placement toward integrated procedural excellence. Organizations that support clinician education, generate credible evidence, address regional access needs, and align EVH with measurable patient and hospital outcomes will be best positioned to influence the future of minimally invasive vessel harvesting.

Product Code: MRR-2D668742FF4E

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Endoscopic Vessel Harvesting Market, by Product Category

7.1. Introduction
7.2. Accessories
- 7.2.1. Adapters
- 7.2.2. Cannulas
- 7.2.3. Insufflation Tubing
7.3. Instruments
7.4. Systems
- 7.4.1. Automated Harvest System
- 7.4.2. Manual Harvest System

8. Endoscopic Vessel Harvesting Market, by Energy Source

8.1. Introduction
8.2. Electrocautery-based
8.3. Bipolar RF-based
8.4. Ultrasonic-based
8.5. Thermal Energy-based

9. Endoscopic Vessel Harvesting Market, by Patient Type

9.1. Introduction
9.2. Adult Patients
9.3. Geriatric Patients
9.4. Pediatric Patients

10. Endoscopic Vessel Harvesting Market, by Application

10.1. Introduction
10.2. Coronary Artery Bypass Graft
10.3. Peripheral Vascular Surgery
- 10.3.1. Dialysis Access
- 10.3.2. Lower Limb Reconstruction

11. Endoscopic Vessel Harvesting Market, by End User

11.1. Introduction
11.2. Ambulatory Surgical Center
11.3. Hospitals

12. Endoscopic Vessel Harvesting Market, by Region

12.1. Asia-Pacific
12.2. Europe
12.3. North America
12.4. Latin America
12.5. Africa
12.6. Middle East

13. Endoscopic Vessel Harvesting Market, by Group

13.1. NATO
13.2. G7
13.3. BRICS
13.4. European Union
13.5. ASEAN
13.6. GCC

14. Endoscopic Vessel Harvesting Market, by Country

14.1. China
14.2. United States
14.3. Japan
14.4. India
14.5. Germany
14.6. United Kingdom
14.7. Australia
14.8. France
14.9. South Korea
14.10. Italy
14.11. Canada
14.12. Russia
14.13. Brazil
14.14. Mexico
14.15. Spain

15. Competitive Landscape

15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
- 15.3.1. Concentration Ratio (CR)
- 15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025

16. Company Profiles

16.1. Ackermann Instrumente GmbH
16.2. Aohua Endoscopy Co., Ltd.
16.3. B. Braun Melsungen AG
16.4. Delacroix-Chevalier
16.5. Erbe Group
16.6. Fujifilm Holdings Corporation
16.7. Getinge AB
16.8. Karl Storz SE & Co. KG
16.9. Lemke Vision GmbH
16.10. Medit Inc.
16.11. Meril Life Sciences Pvt. Ltd.
16.12. Microline Surgical Inc.
16.13. Olympus Corporation
16.14. Optomic Espana S.A.
16.15. Richard Wolf GmbH
16.16. Scholly Fiberoptic GmbH
16.17. Stryker Corporation
16.18. Surgmed Group
16.19. Terumo Corporation
16.20. Tonglu WANHE Medical Instrument Co., Ltd.
16.21. Vathin Medical Instrument Co., Ltd.
16.22. XION GmbH
16.23. Zimmer Biomet Holdings, Inc.